HK Inno N Corp
195940
Company Profile
Business description
HK Inno N Corp operates in the Ethical Drugs (ETC) and Health & Beauty (H&B) businesses. Key products in the ETC sector include K-Cap, Lovajet, and Akinzio, while key products in the H&B sector include Condition, Hogaesu, and B-Ones. The company operates in two segments: Pharmaceutical division; and Health and Beauty division. It generates maximum revenue from Pharmaceutical division. Geographically, it operates in Domestic and Foreign markets.
Contact
No. 239, Osongsaengmyeong 2-ro
Osong-eup, Heungdeok-gu
Chungcheongbuk-do
Cheongju-si
KORT: +82 3151764000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,703
Stocks News & Analysis
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
stocks
Undervalued ASX miner hits production homerun
Record volumes, lower costs and reduced debt underpin a stronger earnings outlook for ASX miner.
stocks
Meta earnings: AI-driven improvements in top line fail to impress investors
We reiterate our fair value estimate for wide-moat Meta and view the after-market selloff as an overreaction
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,137.00 | 70.20 | -0.76% |
| CAC 40 | 8,509.64 | 24.00 | 0.28% |
| DAX 40 | 25,629.24 | 17.21 | 0.07% |
| Dow JONES (US) | 52,452.01 | 243.95 | 0.47% |
| FTSE 100 | 10,868.05 | 29.22 | -0.27% |
| HKSE | 25,884.43 | 25.55 | 0.10% |
| NASDAQ | 25,262.31 | 140.14 | 0.56% |
| Nikkei 225 | 64,362.02 | 2,494.59 | 4.03% |
| NZX 50 Index | 13,699.28 | 63.50 | -0.46% |
| S&P 500 | 7,469.85 | 32.22 | 0.43% |
| S&P/ASX 200 | 8,976.80 | 73.10 | -0.81% |
| SSE Composite Index | 3,832.26 | 27.57 | 0.72% |